R&D Systems™ Human MAG/Siglec-4a Fc Chimera, Carrier-Free Recombinant Protein
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility.
Manufacturer: R&D Systems™ 8940MG050
DescriptionThe Recombinant Human MAG/Siglec-4a Fc Chimera Protein is derived from HEK293. The Recombinant Human MAG/Siglec-4a Fc Chimera Protein has been validated for the following applications: Bioactivity.
|Human embryonic kidney cell, HEK293-derived Human MAG (Gly20-Pro516) Accession # P20916, N-terminus; IEGRMD; Human IgG1 (Pro100-Lys330), C-terminus|
|>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie™ Blue Staining|
|Human embryonic kidney cell,HEK293-derived human MAG/Siglec-4a protein, (N-terminus) Human MAG (Gly20-Pro516) Accession &Num; P20916 IEGRMD Human IgG1 (Pro100-Lys330) (C-terminus)|
|<0.10 EU per 1μg of the protein by the LAL method.|
|Measured by its ability to inhibit neurite outgrowth of dissociated E13 chick embryonic dorsal root ganglia (DRG) neurons. When immobilized as a 3μL droplet containing 200 ng on a nitrocellulose coated microplate, Recombinant Human MAG/Siglec-4a Fc Chimera is able to significantly inhibit neurite outgrowth.|
|Theoretical M.W.: 81kDa|
|Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution.|
|GMAsialic acid binding Ig-like lectin 4A, myelin associated glycoprotein, myelin-associated glycoprotein, sialic acid-binding immunoglobulin-like lectin 4A, Siglec4a, SIGLEC-4A, S-MAG|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok